Skip to content

Effects of Tualang honey on oxidative stress status, inflammation and lipid profiles in chronic smokers

Effects of Tualang honey on oxidative stress status, inflammation and lipid profiles in chronic male smokers

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615001236583
Enrollment
64
Registered
2015-11-11
Start date
2012-09-03
Completion date
2012-09-18
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Elevated oxidative stress, inflammation and alteration in lipid profiles in smokers have been proposed as among the major factors that contribute to the development of smoking-related cardiovascular disease. However, the possible beneficial effect of Tualang honey that has antioxidant, anti-inflammatory and antilipid properties among smokers has yet been reported. The aims of this study, therefore, to determine the effects of Tualang Honey supplementation on oxidative stress markers, inflammatory markers and lipid profiles in chronic smokers.

Interventions

Tualang honey supplementation 20 g daily orally for 12 weeks. Honey is in liquid form packed in a sachet (20 g per sachet). Honey must be taken alone before meal in the morning. Participants are required to return the empty sachet to ensure or monitor compliance.

Sponsors

Universiti Sains Malaysia
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
Male
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

For Non-smoker group - no history of smoking - no history of exposure to environmental tobacco smoke For smoker group - smoke at least 10 cigarettes/day for more than 5 years or 2.5 pack-years

Exclusion criteria

- Regular consumption of multivitamins and/or dietary supplements 3 months before participation in the study - presence of diabetes mellitus, hypertension, hyperlipidemia or cardiovascular diseases - obese (BMI>30kg/m2) - taking alcohol - presence of severe infection

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 10, 2026